A Randomized, Double-Blind Study Evaluating Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus the Combination of Emtricitabine and Tenofovir DF for the Treatment of Chronic Hepatitis B

Trial Profile

A Randomized, Double-Blind Study Evaluating Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus the Combination of Emtricitabine and Tenofovir DF for the Treatment of Chronic Hepatitis B

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Emtricitabine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 28 Apr 2013 Results presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00507507).
    • 08 Jul 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12607000371493).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top